Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Jul 28, 2023
  • participants needed
    600
  • sponsor
    GlaxoSmithKline
Updated on 21 April 2021
cancer
measurable disease
carcinoma
squamous cell carcinoma
dental caries
pembrolizumab
primary tumor
squamous cell carcinoma of head and neck
oropharyngeal
human papillomavirus
carcinoma of oropharynx
metastatic head and neck squamous cell carcinoma
gsk3359609

Summary

The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) >=1 R/M HNSCC. Approximately 600 participants will be enrolled in the study and will have a follow-up until death.

Details
Condition head and neck cancer
Treatment Placebo, Pembrolizumab, GSK3359609, feladilimab
Clinical Study IdentifierNCT04128696
SponsorGlaxoSmithKline
Last Modified on21 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Is your age greater than or equal to 18 yrs?
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have any of these conditions: Do you have head and neck cancer??
Do you have head and neck cancer?
Gender: Male or Female
Capable of giving signed informed consent
Male or female, age >=18 years
Histological or cytological documentation of Head and Neck Squamous Cell Carcinoma (HNSCC) that is considered incurable by local therapies
Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx
No prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of multimodal treatment for locally advanced disease)
Measurable disease per RECIST version 1.1 guidelines
ECOG Performance PS score of 0 or 1
Adequate organ function
Life expectancy of at least 12 weeks
Female participants: must not be pregnant, not breastfeeding, and at least one of the following conditions apply
Not a woman of childbearing potential (WOCBP)
A WOCBP who agrees to use a method of birth control from 30 days prior to randomization and for at least 120 days after the last dose of study treatment
Male participants with female partners of child-bearing potential: must agree to use a highly effective contraception while receiving study treatment and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
Provide tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) acquired within 2 years prior to randomization for PD-L1 immunohistochemistry (IHC) testing by central laboratory
Have PD-L1 IHC CPS 1 status by central laboratory testing
Have results from testing of Human Papilloma Virus (HPV) status for oropharyngeal cancer

Exclusion Criteria

Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter
Major surgery 28 days prior to randomization
Toxicity from previous anticancer treatment that includes toxicity related to prior treatment that has not resolved to Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be Grade 2)
Received transfusion of blood products or administration of colony stimulating factors within 14 days prior to randomization
Central nervous system (CNS) metastases, with the following exception: Participants with asymptomatic CNS metastases who are clinically stable and have no requirement for steroids for at least 14 days prior to randomization
Invasive malignancy or history of invasive malignancy other than disease under study within the last 3 years, except as noted below
Any other invasive malignancy for which the participant was definitively treated, has been disease-free for 3 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical study
Autoimmune disease or syndrome that required systemic treatment within the past 2 years
Has a diagnosis of immunodeficiency or is receiving systemic steroids (10 mg oral prednisone per day or equivalent) or other immunosuppressive agents within 7 days prior to randomization
Receipt of any live vaccine within 30 days prior randomization
Prior allogeneic/autologous bone marrow or solid organ transplantation
Has current pneumonitis or history of non-infectious pneumonitis that required steroids or other immunosuppressive agents
Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions
Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess
Recent history of allergen desensitization therapy within 4 weeks of randomization
History or evidence of cardiac abnormalities within the 6 months prior to randomization
Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
Active infection requiring systemic therapy
Known HIV infection, or positive test for hepatitis B active infection (presence of hepatitis B surface antigen), or hepatitis C active infection
History of severe hypersensitivity to monoclonal antibodies or any ingredient used in the study treatment formulations
Known history of active tuberculosis
Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator
Is currently participating in (unless in follow-up phase and 4 weeks have elapsed from last dose of prior investigational agent), or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to date of randomization
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note